New letters urge the Centers for Medicare & Medicaid Services to expand Medicare and Medicaid to include FDA-approved anti-obesity medications.

Senators grilled Robert F. Kennedy Jr. on if and how he would reform Medicaid and Medicare during his first confirmation hearing to become the next secretary of Health and Human Services.

CMS said it is considering ways to bring "greater transparency" to the Medicare drug pricing negotiation program mandated under the Inflation Reduction Act of 2022.

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — a move applauded by experts as they await the impact of the first-round of discounts anticipated next year.

The Centers for Medicare & Medicaid Services (CMS) finalized significant updates to the Medicare 60-Day Rule, which governs how providers

The new Trump administration should seize the opportunity to change the Medicare drug price negotiation program by introducing floors.

Healthcare Management Solutions LLC can perform a $41 million auditing services task order for the Centers of Medicare and Medicaid Services despite the agency’s improper discussions, the US Court of Federal Claims said.

An expanding prohibition on third-party financial guarantees could lead to more nursing home using lawsuits to collect unpaid debt.

A provision about insulin in the Inflation Reduction Act is conflated with a 2022 executive order by former President Joe Biden on lowering prescription drug costs in posts online that suggest President Donald Trump has canceled the $35 insulin co-pay cap for certain Medicare programs.

The Centers for Medicare & Medicaid Services (CMS) recently announced two significant updates to Workers’ Compensation Medicare Set-Aside

CMS issued the industry-wide ratings the next month. Among large insurers, UnitedHealthcare experienced one of the most dramatic drops in scores. In its lawsuit, the UnitedHealth Group subsidiary alleged the decline improperly cost the company “tens of millions” in federal payments.

The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare negotiation. The CMS listed Ozempic, Rybelsus and Wegovy — all forms of